Data from an open-label, fixed-sequence study showed that although sacubitril inhibited organic anion-transporting polypeptides (OATP)1B1 and OATP1B3 in vitro, this did not translate to any clinically ...

Please provide your email address to receive an email when new articles are posted on . Sacubitril/valsartan showed benefit across the spectrum of left ventricular ejection fraction in stable patients ...

Please provide your email address to receive an email when new articles are posted on . Presenting data from the trial during the American College of Cardiology Scientific Session, Marc Pfeffer, MD, ...

Treatment with sacubitril/valsartan (Entresto, Novartis) in patients with heart failure and preserved ejection fraction (HFpEF) failed to show a significant benefit for the primary clinical end point ...

Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker ...

CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less likely ...

Add Yahoo as a preferred source to see more of our stories on Google. Findings support sacubitril/valsartan's role as a potentially valuable late-line therapy for resistant hypertension. Credit: ABO ...

Treatment with sacubitril/valsartan, a pillar of therapy for patients with chronic heart failure with below-normal ejection fraction, came suggestively close to showing efficacy for preventing ...

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting ...

Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to ...